When should a patient with an estimated glomerular filtration rate of 28 mL/min/1.73 m² (stage 4 chronic kidney disease) be referred to a nephrologist?

When to Refer a Patient with Stage 4 CKD (eGFR 28 mL/min/1.73 m²) to Nephrology

A patient with an eGFR of 28 mL/min/1.73 m² (stage 4 CKD) should be referred to a nephrologist immediately—this is an absolute indication for specialist care. 1, 2, 3, 4

Absolute Referral Threshold

Your patient meets the universal referral criterion: eGFR <30 mL/min/1.73 m² (CKD stage G4-G5). 1, 2, 3, 4 This threshold is supported by multiple international guidelines:

• The National Kidney Foundation (NKF) K/DOQI guidelines recommend nephrologist participation in care when GFR falls below 30 mL/min/1.73 m². 1
• KDIGO 2024 guidelines mandate referral for eGFR <30 mL/min/1.73 m². 2, 3
• The 2015 American Diabetes Association guidelines recommend referral when eGFR <30 mL/min/1.73 m². 5

The rationale is clear: at this level of kidney function, complications of CKD (anemia, metabolic bone disease, metabolic acidosis, hyperkalemia, malnutrition) become highly prevalent and require specialist management. 1 Additionally, preparation for renal replacement therapy should begin at stage 4 CKD, well before uremic symptoms develop. 1

Why Immediate Referral Matters

Late referral—defined as nephrology contact less than 1 year before dialysis initiation—is associated with increased mortality after dialysis starts. 1, 4 Studies demonstrate that consultation when stage 4 CKD develops reduces cost, improves quality of care, and delays dialysis. 5

At eGFR 28 mL/min/1.73 m², your patient is at high risk for progression to kidney failure. Even if the decline has been stable, specialist input is essential to:

• Manage CKD-specific complications (anemia, secondary hyperparathyroidism, metabolic acidosis, hyperkalemia). 1, 2, 4
• Optimize nephroprotective therapies (ACE-inhibitors/ARBs, SGLT2 inhibitors if applicable). 5, 4
• Plan for renal replacement therapy (dialysis access creation, transplant evaluation, conservative care discussions). 1, 2, 3
• Adjust medication dosing to prevent toxicity. 1

Additional Referral Triggers to Assess

While eGFR <30 mL/min/1.73 m² alone mandates referral, evaluate whether your patient has other high-risk features that further underscore urgency:

• Significant albuminuria (ACR ≥300 mg/g or protein excretion >1 g/day). 2, 3, 4
• Rapid progression (eGFR decline >5 mL/min/1.73 m² per year or >20% decline on repeat testing). 2, 3, 4
• Resistant hypertension (uncontrolled on ≥4 antihypertensive agents). 2, 3, 4
• Persistent electrolyte abnormalities (hyperkalemia, hypokalemia, metabolic acidosis). 2, 3, 4
• Hematuria (>20 RBCs per high-power field or red cell casts). 2, 3, 4
• Uncertain etiology (absence of diabetic retinopathy in a diabetic patient, active urinary sediment, or rapid decline without clear cause). 5, 2, 4

Pre-Referral Workup

Before or concurrent with referral, ensure the following laboratory tests are completed to facilitate the nephrologist's evaluation:

Essential Tests

• Serum creatinine with eGFR (CKD-EPI equation preferred). 4
• Urinalysis with microscopy to detect casts, red cells, and other sediment. 4
• Urine albumin-to-creatinine ratio (ACR) or protein-to-creatinine ratio (PCR). 4
• Comprehensive metabolic panel (electrolytes, calcium, phosphorus, bicarbonate). 4
• Complete blood count to screen for anemia. 4
• Hemoglobin A1c if diabetes is present or suspected. 4
• Lipid panel for cardiovascular risk assessment. 4

Additional Tests for Stage 4 CKD

• Parathyroid hormone (PTH) level. 5, 4
• 25-hydroxyvitamin D level. 5, 4
• Renal ultrasound if obstruction, structural abnormality, or hereditary disease is suspected. 4

Medication Review

• Discontinue NSAIDs and other nephrotoxic agents (contrast media, aminoglycosides). 4, 6
• Document current ACE-inhibitor/ARB therapy and dosing. 4
• Review diuretics and adjust as needed. 4
• Identify over-the-counter, herbal, and supplement use that may be nephrotoxic. 4

Monitoring Frequency at This Stage

Patients with eGFR 30–44 mL/min/1.73 m² should have kidney function reassessed every 3 months. 5, 4 Your patient with eGFR 28 mL/min/1.73 m² falls into this category and requires quarterly monitoring of:

• Serum creatinine and eGFR. 5, 4
• Electrolytes, bicarbonate, calcium, phosphorus, PTH, hemoglobin, and albumin. 5, 4

Common Pitfalls to Avoid

• Do not delay referral because the patient is asymptomatic—uremic symptoms typically do not appear until eGFR <15 mL/min/1.73 m². 1
• Do not assume elderly patients with multiple comorbidities do not benefit from nephrology care—even those not pursuing dialysis benefit from symptom management and conservative care planning. 4
• Do not stop ACE-inhibitors/ARBs precipitously if creatinine rises <30% from baseline after initiation—this is a benign hemodynamic effect. 4
• Do not overlook cardiovascular risk management—patients with CKD are in the highest risk group for cardiovascular events, which are more common than kidney failure. 1

Role Division: Primary Care vs. Nephrology

Primary care should continue to manage cardiovascular risk factors, blood pressure, glycemic control, and avoidance of nephrotoxins (e.g., NSAIDs, contrast agents) to slow CKD progression. 4, 6

Nephrologists focus on CKD-specific complications such as anemia, mineral-bone disorder, metabolic acidosis, and preparation for renal replacement therapy. 4, 6